Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsDan Chalothorn, Lori C. Morton, KehDih Lai
Estimating the term…
The present disclosure provides antibodies that bind to the A2 domain of Factor XI (FXI) and methods of using the same. According to certain embodiments, the antibodies are antagonist antibodies that inhibit blood clot formation via the intrinsic pathway without affecting hemostasis, as shown by their effect on prolonging aPTT without affecting PT. As such, these antagonist antibodies may be used to treat blood clotting diseases or disorders or treatment regimens that have clot formation as a risk factor, such as, but not limited to atrial fibrillation. In certain embodiments, the disclosure includes antibodies that bind FXI and mediate clot formation or thrombogenesis. The antibodies of the disclosure may be fully human, non-naturally occurring antibodies.
-29. (canceled)
An isolated nucleic acid molecule comprising a polynucleotide sequence that encodes a heavy chain variable region (HCVR) of an antibody, or antigen-binding fragment thereof, that binds to the apple 2 (A2) domain of coagulation factor XI (FXI), wherein the HCVR comprises the amino acid sequence of SEQ ID NO:
An isolated nucleic acid molecule comprising a polynucleotide sequence that encodes a light chain variable region (LCVR) of an antibody, or antigen-binding fragment thereof, that binds to the apple 2 (A2) domain of coagulation factor XI (FXI), wherein the LCVR comprises the amino acid sequence of SEQ ID NO:
An isolated nucleic acid molecule comprising a polynucleotide sequence that encodes a heavy chain variable region (HCVR) and a light chain variable region (LCVR) of an antibody, or antigen-binding fragment thereof, that binds to the apple 2 (A2) domain of coagulation factor XI (FXI), wherein the HCVR comprises the amino acid sequence of SEQ ID NO:
Dependencies are inferred from the claim text.